Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 44,328,000 | 41,950,000 | 40,109,000 | 43,653,000 | 43,075,000 |
| Cost of Goods | 19,319,000 | 18,706,000 | 17,975,000 | 19,142,000 | 18,537,000 |
| Gross Profit | 25,009,000 | 23,244,000 | 22,134,000 | 24,511,000 | 24,538,000 |
| Operating Expenses | 16,956,000 | 16,419,000 | 15,656,000 | 16,149,000 | 16,113,000 |
| Operating Income | 8,053,000 | 6,825,000 | 6,478,000 | 8,362,000 | 8,425,000 |
| Interest Expense | 185,000 | 559,000 | 637,000 | 558,000 | 533,000 |
| Other Income | 598,000 | 747,000 | 823,000 | 502,000 | 319,000 |
| Pre-tax Income | 8,466,000 | 7,013,000 | 6,664,000 | 8,306,000 | 8,211,000 |
| Income Tax | 1,942,000 | -6,389,000 | 941,000 | 1,373,000 | 1,140,000 |
| Net Income Continuous | 6,524,000 | 13,402,000 | 5,723,000 | 6,933,000 | 7,071,000 |
| Net Income | $6,524,000 | $13,402,000 | $5,723,000 | $6,933,000 | $7,071,000 |
| EPS Basic Total Ops | N/A | 7.67 | 3.28 | 3.94 | 3.97 |
| EPS Basic Continuous Ops | N/A | 7.70 | 3.29 | 3.95 | 3.98 |
| EPS Diluted Total Ops | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 |
| EPS Diluted Continuous Ops | 3.73 | 7.67 | 3.27 | 3.93 | 3.95 |
| EPS Diluted Before Non-Recurring Items | 5.15 | 4.67 | 4.44 | 5.34 | 5.21 |
| EBITDA(a) | $8,053,000 | $10,043,000 | $9,721,000 | $11,629,000 | $11,963,000 |